Document is current
Any future updates will be listed below
-
Authors
Tang, Jieting
Wang, Yongfeng
Han, Tao
Mao, Qing
Cheng, Jun
Ding, Huiguo
Shang, Jia
Zhang, Qin
Niu, Junqi
Ji, Feng
Chen, Chengwei
Jia, Jidong
Jiang, Xiangjun
Lv, Nonghua
Gao, Yueqiu
Wang, Zhenghua
Wei, Zhong
Chen, Yingxuan
Zeng, Minde
Mao, Yimin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01349348 at ClinicalTrials.govDocuments that mention this clinical trial
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
https://doi.org/10.1186/s12876-020-01536-0
-
Funding
Funding for this research was provided by:
Zhejiang Otsuka Pharmaceuticals Co., Ltd.
Otsuka Beijing Research Institute
- License Information
-
More Information
Article History
Received: 14 January 2020
Accepted: 10 November 2020
First Online: 19 November 2020
Ethics approval and consent to participate
: This trial was reviewed and approved by the Ethics Committee of Shanghai Renji Hospital or the ethics committees of individual participating institutions. All eligible patients provided written informed consent prior to enrollment in the trial.
: Not applicable.
: The authors declare that they have no competing interests.
